“Global Antibiotic Resistance Market is anticipated to grow on account of growing incidences of infectious diseases and burden of antibiotic resistant infections,” says Visiongain report

04 September 2019
Pharma

Visiongain has launched a new pharma report Antibiotic Resistance Market Report: By Disease (CUTI, CIAI, BSI, CDI, ABSSSI, HABP/VABP, CABP), by Pathology (Acinetobacter Baumannii, Pseudomonas Aeruginosa, Staphylococcus Aureus, E. coli/K. Pneumoniae, Streptococcus Pneumoniae, Clostridium Difficile, Enterococcus Faecium, Haemophilus Influenzae), by Drug Class (Oxazolidinones, Lipoglycopeptides, Tetracyclines, Cephalosporins, Combination Therapies, Others) and by Region.

Global Antibiotic Resistance Market is anticipated to grow on account of growing incidences of infectious diseases and burden of antibiotic resistant infections. The global antibiotic resistance market is anticipated to grow at a lucrative CAGR of 5.4% and anticipated to reach USD 14.14 Billion by 2029.

Antibiotic resistance is spreading rapidly across the globe. New mechanisms of resistance are emerging and spreading worldwide, threatening capacity of companies to treat prevalent infectious diseases. An increasing list of infections such as tuberculosis, pneumonia, gonorrhea, blood poisoning, and nutritional illnesses is becoming more difficult and sometimes impossible to treat as antibiotics become less efficient.

Where antibiotics can be purchased without a prescription for human or animal use, the development and spread of resistance is exacerbated. Similarly, antibiotics are often over-prescribed by health employees without conventional treatment guidelines and are over-used by the public.

Without immediate action, we are moving towards a post-antibiotic age where prevalent infections and minor wounds can be killed again. Antibiotic resistance has the ability to impact individuals at any point of life, as well as the healthcare, veterinary and farming sectors, making it one of the most pressing public health issues in the world. More than 2 million individuals are infected with antibiotic-resistant bacteria every year in the United States, resulting in the death of at least 24,000 individuals.

North America holds majority of market share followed by Europe and the growth is attributed to new drug launches and high supplement cost. Europe holds a significant market share and is anticipated to grow at a lucrative growth rate. Also, as per The Lancet Infectious Diseases, there is a burden of antibiotic resistant infections across European countries. Annually more than 32000 people die from antibiotic resistant bacterial infections in the European region and the burden is comparable to that from TB, HIV and influenza combined.

Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations and launching new products in order to strengthen their position in the global single-cell genomics market. Companies are also expanding their R&D, distribution, and management facilities in order to expand their business and to hold a competitive edge in the market.

For example, through public-private partnerships, a joint initiative of the World Health Organization and Drugs for Neglected Diseases Initiative, GARDP promotes R&D in the field of antibiotics. By 2023, the partnership seeks at developing and delivering up to four new medicines by improving current antibiotics and accelerating the introduction of fresh antibiotic drugs.

The comprehensive market report features companies such as Allergan, AmpliPhi Biosciences, Biolytx Pharmaceuticals, BioVersys GmbH, Macrolide Pharmaceuticals, Melinta Therapeutics, Merck, Pfizer, Phage Technologies S.A, SelectX Pharmaceuticals, Inc. and Wockhardt therapeutics among other prominent players.

Also the research study offers market estimation and forecast for the period ranging 2019–2029 for global markets such as North America, Latin America, Western Europe, Eastern Europe, Asia Pacific and MEA along with regional sub-markets as U.S., Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Nordic, Benelux, Russia, Poland, India, Japan, China, Australia, ASEAN, GCC, South Africa and North Africa.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

 

Recent News

Visiongain Publishes Biopharmaceuticals Contract Manufacturing Market Report 2022-2032

Ageing population will be more susceptible to such diseases and is one of the key factors driving the growth of the global biological drugs market. In most of the developed world, the share of elderly population is almost touching a quarter of the population.

26 January 2022

Read

Visiongain Publishes Topical Drug Delivery Market Report 2022-2032

Some of the factors driving the market growth are the increasing prevalence of skin and eye diseases, high incidences of burn incidences and the growing prevalence of diabetes.

26 January 2022

Read

Visiongain Publishes Decentralized Clinical Trials Market Report 2022-2032

The growing adoption advanced e-clinical solutions, rising focus on clinical research, increasing investment in R&D, and adoption of decentralized clinical trials by biopharmaceutical companies are some of the major factors that drive the growth of the global decentralized clinical trials market.

24 January 2022

Read

Visiongain Publishes Nasal Drug Delivery Technology Market Report 2022-2032

The nasal drug delivery market will expand rapidly due to rising patient preference for nasal medication delivery due to ease of administration and efficacy, increased self-administration practises, and increased demand for home healthcare equipment.

18 January 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever